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Background: The goal of this study was to assess the efﬁcacy of cryotherapy with dynamic intermittent
compression (CDIC) in relieving postoperative pain, decreasing blood loss, and improving functional
scores after revision total knee arthroplasty (rTKA).
Methods: We conducted a prospective case control study (level of evidence: I) to evaluate the efﬁcacy of
CDIC on postoperative bleeding, pain, and functional outcomes after rTKA. Forty three cases were
included at a single institution and divided in 2 groups: a control group without CDIC (n ¼ 19) and an
experimental group with CDIC (n ¼ 24). Bleeding was evaluated by calculating total blood loss, pain at
rest was evaluated with a visual analog scale on postoperative day 3, and function was assessed using the
Oxford score at 6 months postoperatively. The comparative analysis was performed using the Fisher
exact test.
Results: The CDIC group had signiﬁcantly lower total blood loss (260 vs 465 mL; P < .05), signiﬁcantly
less pain on day 3 (1 vs 3; P < .05), and a signiﬁcantly higher functional score (42 vs 40; P < .05) than the
control group.
Conclusion: This is the ﬁrst report dealing with the use of CDIC after rTKA. According to our results, it
improves the recoveryof patientswhounderwent rTKA; thus, it should be integrated intoourdailypractice.Revision total knee arthroplasty (rTKA) procedures cause blood
loss. Postoperative anemia is associated with a higher risk of
infection [1], patient dissatisfaction [2], and postoperative blood
transfusion with its inherent risks [3].
rTKA is a major orthopedic procedure that causes soft tissue
damages that contribute to localized pain, which in turn reduces
range of motion and causes persistent quadriceps atrophy [4]. Sig
niﬁcant blood loss after this procedure (up to 1.5 L) can lead to sys
temic complications [3]. Despite progress in multimodal analgesia
and anesthetic methods, total knee arthroplasty (TKA) is a painful
surgery [4]. Nonpharmacologic treatments can also play a role, most
notably cryotherapy which decreases the local metabolism, thereby
reducing blood loss and pain [5]. This technique has minimal dis
advantages relative to its potential beneﬁts [6].d any potential or pertinent 
 conﬂict with this work. For 
.1016/j.arth.2017.03.052.
ent d'Orthopedie Traumato-
ace du Docteur Baylac, TSA New devices that combine cryotherapy with dynamic inter
mittent compression (CDIC) have recently been introduced. These
devices provide a dry cold temperature and maintain a consistent
temperature for an extended period of time [4,7]. Although the
beneﬁts of these systems were demonstrated in primary TKA [7]
and anterior cruciate ligament reconstruction [8], we did not ﬁnd
any published studies evaluating the effect of CDIC in patients
undergoing rTKA.
Our hypothesis was that use of CDIC would reduce total blood
loss after rTKA. The main objective of this study was to assess its
efﬁcacy in terms of postoperative blood loss. Patients who under
went rTKA were split into 2 matched groups for comparisons: one
group with CDIC and the other one without. The other objectives
were to compare blood transfusion rates, pain, functional scores,
and complication rates in both groups.
Patients and Methods
This was a single institution, prospective, case control study
(level of evidence: 3). It was approved by our hospital's research
ethics committee (Number 01 0115).
Table 1
Baseline Characteristics and Surgery Related Data for the Cohort.
Characteristics Control Group
(n 19)
CDIC Group
(n 24)
P Value
Baseline characteristics
Age, mean (SD), y 66.5 (9.7) 70 (13.9) .86
Gender, F/M 8/11 8/16 .78
BMI, mean (SD), kg/m2 29.7 (4.6) 29.7 (4.7) .89
Preoperative anticoagulants, n (%) 6 (32) 3 (13) .15
ASA score, n (%)
1 1 (5) 4 (17) .17
2 8 (42) 14 (58)
3 10 (53) 6 (25)
Surgery-related data
Surgery time, mean (SD), min 120 (40.2) 118 (43.3) .84
Tourniquet time, mean (SD), min 98 (27.4) 100 (29.3) .98
TT osteotomy, n (%) 5 (26) 4 (17) .48
Patella resurfacing, n (%) 8 (42) 6 (25) .39
ASA, American Society of Anesthesiologists; BMI, body mass index; CDIC, cryo-
therapy with dynamic intermittent compression; F, female; M, male; SD, standard
deviation; TT, tibial tubercle.Patients
All patients who underwent single stage rTKA from January
2013 to January 2015 were included.
Patients were excluded when a 2 stage revision or a partial
revision was performed. They were also excluded if they had a
contraindication to CDIC, such as history of deep vein thrombosis,
coagulation disorder, or skin damage at the device application site.
Forty three patients were included (27 males and 16 females).
The revisions procedures were carried out with rotating hinge
knee prosthesis (RH Knee NexGen; Zimmer, Warsaw, IN) in all
cases. A tibial tubercle osteotomy was needed in 9 cases, and the
patella was resurfaced in 14 cases during the revision procedure.
The anesthesia and postoperative analgesia protocols used were
standardized and similar in the 2 groups. Anticoagulant therapy
was initiated 6 hours after the end of surgery in all patients.
The procedure was performed with a tourniquet in all cases. It
was released before closing the wound to realize complete hemo
stasis. The mean procedure duration was 120 minutes (90 140
minutes).
Methods
The population was divided into 2 groups: a control group
without CDIC and an experimental one with CDIC. The de
mographics data in these 2 groups were comparable (Table 1). The
patients in the control group were included between January 2013
and April 2014. The patients in the CDIC group were included be
tween May 2014 and January 2015.
The CDIC device used was the Game Ready system (CoolSystems
Inc, Concord, CA). It comes with an anatomic wrap that is applied to
the knee. This wrap circulates precooled compressed air and water.
The temperature controlled unit generates a dry cold temperature;
this is more comfortable for the patient than a wet cold tempera
ture, thereby limiting the risk of maceration, bandage deterioration,
and skin lesions. The wrap is covered with a removable, washable
cover for the patient's health and comfort. Thewrap is connected to
a portable control unit. The compression is applied intermittently
depending on the protocol selected. The surgery support staff was
given speciﬁc training on how to use the CDIC.
The following protocol was used:
Application: after bandaging, in the operating room and before
transfer to recovery room
Intensity: programme 3 (30 minute on/off cycles)Temperature: 8C
Application duration: two 8 hour cycles over a 24 hour period
and
Treatment duration: 72 hours postoperative.
The control group was treated with regular cold application
(4 hours per day) using a cold pack.
The following parameters were measured in both groups: total
blood loss, hemoglobin and hematocrit levels on D 1, Dþ1, and
Dþ5, transfusion volume and rate (red cell concentrate [RCC] units),
pain on postoperative day 3, functional outcomes based on the
Oxford score at 6 months postoperative, and the number of com
plications recorded at 6 months postoperative.
Total blood loss was calculated using the preoperative (D 1)
and postoperative (Dþ5) laboratory test results according to the
Merculiari formula [9]:
Total blood loss VST  Hctpre Hctpost D5

þ volume of retransfused RCC*
where the patient's total blood volume k1  height (m)3 þ k2 
mass (kg) þ k3for men: k1 0.3669, k2 0.03219, and k3 0.6041;
and for women: k1 0.3561, k2 0.03308, and k3 0.1833,
Hctpre initial preoperative Hct, Hctpost-D5 Hct on the morning of
the ﬁfth postoperative day.
When transfusion was performed (allogenic or autologous), the
total blood loss was equal to the blood loss calculated from the
change in hematocrit plus the volume transfused [10].
The indication for RCC transfusion in our surgical unit is stan
dardized to Hb <8 g/dL and/or patient with symptomatic anemia.
Postoperative pain at rest was measured by the surgery unit's
nurse using a visual analog scale on the third day postoperative and
by looking at the cumulative morphine use on the ﬁfth post
operative day, expressed in morphine equivalent dose (in mg).
The Oxford score [11] was collected preoperatively and post
operatively using the validated French version of the questionnaire
[12]. The questionnaire was ﬁlled out during a follow up visit 6
months after the procedure.Statistical Analysis
Cohort characteristics are presented as numbers, means, stan
dard deviations, and ranges. The normal distribution of the data
was assessed using the Kolmogorov Smirnov test. For variables that
were not normally distributed, datawere analyzed using theMann
Whitney test for independent samples and the Wilcoxon signed
rank test for dependent samples. Comparison of observed pro
portions was performed using the Fisher exact test. Statistical
analysis was carried out using SPSS 18 statistical software (SPSS Inc,
Chicago, IL), and signiﬁcance was set at P < .05.Results
Blood Loss
The total blood loss was lower in the CDIC group than in the
control group (260 vs 465 mL; P < .05; Table 2). The hemoglobin
and hematocrit levels were similar between groups. The trans
fusion ratewas lower in the CDIC group (8% vs 42%; P < .05), and the
mean lowest hemoglobin level was lower in the control group with
8.5 g/dL (±1.2) vs 9.6 (±1.6); P< .005. In the CDIC group, the number
of RCC units given per patient was lower as well. No differences
were found in any of the other measured blood related parameters.
Table 2
Summary of Variables Measured in Both Groups.
Variables Control Group
(n 19)
CDIC Group
(n 24)
P Value
Blood loss
Hb at D1, mean (SD), g/dL 12.5 (2.1) 13 (1.8) .76
Hb at Dþ5, mean (SD), g/dL 10.4 (1.2) 10.7 (1.3) .31
Hct at D1, mean (SD) 37 (5.9) 39.6 (4.9) .9
Hct at Dþ5, mean (SD) 31 (3.6) 32.7 (3.6) .19
Total blood loss, mean (SD), mL 465 (275) 260 (106) .024
Mean lowest Hb level, g/dL 8.5 9.6 .03
Transfusion rate, % 42 8 .013
Transfusion
Number of RCC units, % (n)
0 58 (11) 92 (22) .023
1 5 (1) 0 (0)
2 26 (5) 4 (1)
3 11 (2) 4 (1)
Pain
VAS Dþ3, mean (SD) 3 (1) 1 (1) .01
Narcotic consumption at Dþ5,
mean (SD), mg
100 (37) 80 (37) 1
Functional score
Oxford score, mean (SD) 40 (2.8) 42 (2.4) NS
Bolded values indicate statistical signiﬁcant differences (<.05).
CDIC, cryotherapy with dynamic intermittent compression; RCC, red cell concen-
trate; Hb, hemoglobin; Hct, hematocrit; SD, standard deviation; VAS, visual analog
scale; NS, non signiﬁcant.
J.Pain
Pain at rest on day 3 was lower in the CDIC group than in the
control group (1 vs 3; P < .05). The cumulative morphine intake at
day 5 was not signiﬁcantly different between groups.
Functional Scores at 6 Months
The Oxford score at 6 months postoperative was higher in the
CDIC group than in the control group (42 vs 40).
Complications
There were 4 complications in the CDIC group and 3 in the
control group. Therewere 2 cases of infection recurrence and 1 case
of deep vein thrombosis in each group, and 1 case of extensor
mechanism disruption in the CDIC group.
Discussion
Our hypothesis was conﬁrmed. The patients in the CDIC group
had lower total blood loss than patients in the control group.
Moreover, the transfusion rate and the pain were lower in the CDIC
group. The functional outcomewas similar between the 2 groups at
6 months postoperative.
This is the ﬁrst study to evaluate the use of CDIC after rTKA. The
blood loss was evaluated using a method previously validated for
rTKA patients [13]. This method provides a complete view of the
total blood loss, as it also takes into account hidden blood loss after
TKA [3]. We did not use the blood volume present in the suction
drains, as in other studies [14]. This blood loss calculationmethod is
not reliable; it overestimates blood losses and can lead to more
blood transfusions [15]. The volume of blood in surgical drains has
never been validated as being an objective measure of blood loss
[13]. There is no correlation between the volume of blood in the
drains and the need for transfusion [16].
CDIC has been used in the sports medicine setting to improve
recovery and to treat ligament and bone injuries [8,16]. It has been
shown that CDIC improves postoperative recovery by stimulatingthe tissue repair process [17]. Generally, these systems are provided
to healthy athletes undergoing a minor procedure compared with
rTKA. We believe that any help is beneﬁcial to a fragile population
such as the one undergoing rTKA.
The contribution of CDIC to postoperative recovery from TKA
has already been demonstrated. Su et al [7] evaluated CDIC in pa
tients undergoing primary TKA and compared it with a control
group. In that study, the patients in the CDIC group used the system
for 5 days after the procedure. They found a lower narcotic intake
and a slight improvement in the functional outcome in patients
using CDIC. We also found a tendency of reduced narcotic use ( 20
mgmorphine equivalents in the CDIC group). This reduced narcotic
intake reduces the side effects inherent to these agents. Patients
feel less medicated and have a better postoperative course.
Advanced cryotherapy was compared with icing only in the post
operative course of TKA in a randomized controlled trial [4]. The
authors concluded that there were no advantages in using
advanced cryotherapy in daily practice, particularly because of the
additional cost associated with these systems. However, more than
one kind of cryotherapy system was used in that study, leading to
variability in the results. Moreover, the blood loss was measured
only through hemoglobin variations, which does not take into ac
count hidden blood loss [3]. In addition, no blood transfusions were
performed, as the patients were undergoing primary TKA. The need
for transfusion is higher during rTKA [18].
Other therapeuticmeans have beenproposed to reduce bleeding
during primary and rTKA procedures. Tranexamic acid has been
shown to be effective in hip and knee arthroplasty [19]. Use of
thrombin based topical hemostatic agents does not have clear cut
beneﬁts. One group has described its beneﬁts in rTKA [13]; how
ever, anemia, atrial ﬁbrillation, and infection have been associated
with this type of product [14,20e22]. These side effects do not come
into play when using CDIC. Thienpont et al [4] bring up the risk of
frostbite in the area where CDIC is applied. This is an extremely
serious complication that would require an additional major soft
tissue procedure [23]. We have not encountered this complication
and have not found any documented cases of frostbite with CDIC.
The present study has certain limitations. First, this was a
multisurgeon study which increases the variability of the results.
However, this also means that the study can be more easily
generalized to current practice. Second, this study was performed
within a highly specialized TKA surgery unit. Because of the use of
advanced anesthesia procedures, analgesic inﬁltration, and pre
ventative multimodal pain management [6], it is possible that a
type II error occurred in our interpretation of the results. However,
the anesthesia and analgesia techniques did not differ between the
control and CDIC groups. Moreover, the transfusion ratedlikely the
most relevant criteria from a clinical point of viewdis subjected to
confounding factors because of the patients' comorbidities.
Although we use a standardized approach, this bias is still present.
Conclusion
The number of rTKA procedures performed each year will
continue to increase [13,24,25]. Since CDIC improves the recovery
of patients undergoing rTKA, it should be integrated into our daily
practice. Prospective randomized trial is necessary to validate the
results of our study.
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